Johnson & Johnson Eyes M&A Opportunities in Ophthalmic Care and Surgical Robotics to Bolster Core Segments

Johnson & Johnson (JNJ.US) CEO Joaquin Duato said on Monday that the company will look for opportunities to merge with or acquire some companies to add value to its key focus areas such as ophthalmic care, surgical robotics, orthopedics, and cardiovascular products.

Duato said, "We will continue to prudently seek opportunities to create value for significant unmet medical needs such as heart failure."

It is reported that Johnson & Johnson completed the acquisition of heart pump manufacturer Abiomed last month for $16.6 billion, and Abiomed will operate as an independent division of its medical device business.

Moreover, the CEO of the company expects that Johnson & Johnson will continue to grow towards the pharmaceutical sales target of $60 billion by 2025 and is confident in exceeding current Wall Street expectations in the target year.

Notably, this medical giant is currently spinning off its consumer healthcare business under the Kenvue brand to focus on pharmaceuticals and medical device operations.